PHASE-II STUDY OF TEMODAL IN THE TREATMENT OF PATIENTS WITH ADVANCED NASOPHARYNGEAL CARCINOMA

Purpose: A single-institution phase II trial of Temodal (temozolomide, SCH52365) in Chinese patients with advance nasopharyngeal carcinoma w as undertaken to determine the efficacy and safety of the drug in this population. Methods: A total of 14 patients with metastatic or locore gionally recurrent nasopharyngeal carcinoma were entered into the stud y. One patient was unevaluable. Temodal was given at doses of 150 or 2 00 mg/m(2) daily on days 1-5 every 28 days. Results, In all, 30 cycles of Temodal were given with no significant toxicity. All 13 (100%) eva luable patients had progressive disease after 2 (84.6%) or 4 (15.4%) c ourses. Conclusion: Temodal given on this schedule has no activity in advanced nasopharyngeal carcinoma.